Keros Therapeutics (NASDAQ:KROS) Sees Unusually-High Trading Volume - Time to Buy?

Key Points

• Keros Therapeutics saw a significant increase in trading volume, with approximately 1.25 million shares traded on Wednesday, up 44% from the previous session.
• Analysts have mixed opinions on the stock, with a consensus rating of Hold and a price target averaging $30.00, although HC Wainwright recently lowered its target from $25.00 to $20.00.
• The company reported a quarterly EPS of ($0.76), beating estimates, but with revenues of only $0.02 million against expectations of $3.83 million.

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 1,253,924 shares changed hands during mid-day trading, an increase of 44% from the previous session's volume of 872,263 shares.The stock last traded at $14.25 and had previously closed at $15.09.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. HC Wainwright cut their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Weiss Ratings reissued a "sell (d)" rating on shares of Keros Therapeutics in a research note on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $30.00.

Keros Therapeutics Trading Down 2.7%

The firm's fifty day moving average price is $15.27 and its 200 day moving average price is $14.17. The firm has a market capitalization of $596.63 million, a PE ratio of 47.78, a PEG ratio of 2.05 and a beta of 0.97.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.38. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The business had revenue of $0.02 million for the quarter, compared to analysts' expectations of $3.83 million. During the same period in the previous year, the company posted ($1.25) EPS. Keros Therapeutics's revenue was up 49002.7% on a year-over-year basis. As a group, research analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Large investors have recently bought and sold shares of the business. FNY Investment Advisers LLC bought a new stake in Keros Therapeutics in the first quarter worth $25,000. CWM LLC boosted its holdings in Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company's stock worth $27,000 after purchasing an additional 2,641 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock worth $42,000 after purchasing an additional 1,888 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in Keros Therapeutics in the third quarter worth $47,000. Finally, Police & Firemen s Retirement System of New Jersey boosted its holdings in Keros Therapeutics by 29.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company's stock worth $110,000 after purchasing an additional 1,892 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.